Metformin as a Tool to Target Aging

Cell Metabolism

Volumn 23, Issue 6, 2016, Pages 1060-1065

  Barzilai, Nir ^a   Crandall, Jill P ^a   Kritchevsky, Stephen B ^b   Espeland, Mark A ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

AGING; CANCER INCIDENCE; COGNITION; DRUG EFFECT; DRUG TARGETING; HUMAN; LIFESPAN; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; LONGEVITY; PHYSIOLOGY;

AGING; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; LONGEVITY; METFORMIN; MODELS, ANIMAL; MODELS, BIOLOGICAL;

EID: 84975491642     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.05.011     Document Type: Note

References (80)

1. K. Alagiakrishnan, S. Sankaralingam, M. Ghosh, L. Mereu, and P. Senior Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease Discov. Med. 16 2013 277 286
2. C. Algire, O. Moiseeva, X. Deschênes-Simard, L. Amrein, L. Petruccelli, E. Birman, B. Viollet, G. Ferbeyre, and M.N. Pollak Metformin reduces endogenous reactive oxygen species and associated DNA damage Cancer Prev. Res. (Phila.) 5 2012 536 543
3. J.S. Allard, E.J. Perez, K. Fukui, P. Carpenter, D.K. Ingram, and R. de Cabo Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice Behav. Brain Res. 301 2016 1 9
4. G. Anfossi, I. Russo, K. Bonomo, and M. Trovati The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus Curr. Vasc. Pharmacol. 8 2010 327 337
5. V.N. Anisimov, and A. Bartke The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer Crit. Rev. Oncol. Hematol. 87 2013 201 223
6. V.N. Anisimov, L.M. Berstein, P.A. Egormin, T.S. Piskunova, I.G. Popovich, M.A. Zabezhinski, M.L. Tyndyk, M.V. Yurova, I.G. Kovalenko, T.E. Poroshina, and A.V. Semenchenko Metformin slows down aging and extends life span of female SHR mice Cell Cycle 7 2008 2769 2773
7. V.N. Anisimov, P.A. Egormin, T.S. Piskunova, I.G. Popovich, M.L. Tyndyk, M.N. Yurova, M.A. Zabezhinski, I.V. Anikin, A.S. Karkach, and A.A. Romanyukha Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo Cell Cycle 9 2010 188 197
8. V.N. Anisimov, L.M. Berstein, I.G. Popovich, M.A. Zabezhinski, P.A. Egormin, T.S. Piskunova, A.V. Semenchenko, M.L. Tyndyk, M.N. Yurova, I.G. Kovalenko, and T.E. Poroshina If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice Aging (Albany, N.Y.) 3 2011 148 157
9. V.R. Aroda, S. Edelstein, R. Goldberg, W.C. Knowler, S. Marcovina, T. Orchard, G.A. Bray, D. Schade, M. Temprosa, N.H. White, and et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study J. Clin. Endocrinol. Metab. 101 2016 1754 1761
10. C.A. Bannister, S.E. Holden, S. Jenkins-Jones, C.L. Morgan, J.P. Halcox, G. Schernthaner, J. Mukherjee, and C.J. Currie Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls Diabetes Obes. Metab. 16 2014 1165 1173
11. A. Bartke, J.C. Wright, J.A. Mattison, D.K. Ingram, R.A. Miller, and G.S. Roth Extending the lifespan of long-lived mice Nature 414 2001 412
12. N. Barzilai, D.M. Huffman, R.H. Muzumdar, and A. Bartke The critical role of metabolic pathways in aging Diabetes 61 2012 1315 1322
13. C. Batandier, B. Guigas, D. Detaille, M.Y. El-Mir, E. Fontaine, M. Rigoulet, and X.M. Leverve The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin J. Bioenerg. Biomembr. 38 2006 33 42
14. H.R. Bridges, A.J. Jones, M.N. Pollak, and J. Hirst Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria Biochem. J. 462 2014 475 487
15. F. Cabreiro, C. Au, K.Y. Leung, N. Vergara-Irigaray, H.M. Cochemé, T. Noori, D. Weinkove, E. Schuster, N.D. Greene, and D. Gems Metformin retards aging in C. Elegans by altering microbial folate and methionine metabolism Cell 153 2013 228 239
16. C. Cheng, C.H. Lin, Y.W. Tsai, C.J. Tsai, P.H. Chou, and T.H. Lan Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis J. Gerontol. A Biol. Sci. Med. Sci. 69 2014 1299 1305
17. K. Cho, J.Y. Chung, S.K. Cho, H.W. Shin, I.J. Jang, J.W. Park, K.S. Yu, and J.Y. Cho Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway Sci. Rep. 5 2015 8145
18. R. de Cabo, D. Carmona-Gutierrez, M. Bernier, M.N. Hall, and F. Madeo The search for antiaging interventions: from elixirs to fasting regimens Cell 157 2014 1515 1526
19. W. De Haes, L. Frooninckx, R. Van Assche, A. Smolders, G. Depuydt, J. Billen, B.P. Braeckman, L. Schoofs, and L. Temmerman Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2 Proc. Natl. Acad. Sci. USA 111 2014 E2501 E2509
20. A. DeCensi, M. Puntoni, A. Guerrieri-Gonzaga, M. Cazzaniga, D. Serrano, M. Lazzeroni, A. Vingiani, O. Gentilini, M. Petrera, G. Viale, and et al. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial Cancer Prev. Res. (Phila.) 8 2015 888 894
21. Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study Diabetes Care 35 2012 731 737
22. F.A. Duca, C.D. Côté, B.A. Rasmussen, M. Zadeh-Tahmasebi, G.A. Rutter, B.M. Filippi, and T.K. Lam Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats Nat. Med. 21 2015 506 511
23. L. Fontana, and L. Partridge Promoting health and longevity through diet: from model organisms to humans Cell 161 2015 106 118
24. L. Fontana, L. Partridge, and V.D. Longo Extending healthy life span - from yeast to humans Science 328 2010 321 326
25. M. Foretz, S. Hébrard, J. Leclerc, E. Zarrinpashneh, M. Soty, G. Mithieux, K. Sakamoto, F. Andreelli, and B. Viollet Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state J. Clin. Invest. 120 2010 2355 2369
26. M. Foretz, B. Guigas, L. Bertrand, M. Pollak, and B. Viollet Metformin: from mechanisms of action to therapies Cell Metab. 20 2014 953 966
27. S. Gandini, M. Puntoni, B.M. Heckman-Stoddard, B.K. Dunn, L. Ford, A. DeCensi, and E. Szabo Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev. Res. (Phila.) 7 2014 867 885
28. R. Goldberg, M. Temprosa, J. Otvos, J. Brunzell, S. Marcovina, K. Mather, R. Arakaki, K. Watson, E. Horton, and E. Barrett-Connor Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program J. Clin. Endocrinol. Metab. 98 2013 3989 3998
29. R. Goldberg, M. Temprosa, V.R. Aroda, E.L. Barrett-Connor, M. Budoff, J. Crandall, D. Dabelea, E.S. Horton, K.J. Mather, T.J. Orchard, and et al. Effect of long-term interventions in the Diabetes Prevention Program (DPP) and its Outcome Study on coronary artery calcium (CAC) Diabetes 64 2015 Supplement 1A, LB5
30. M. Guo, J. Mi, Q.M. Jiang, J.M. Xu, Y.Y. Tang, G. Tian, and B. Wang Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus Clin. Exp. Pharmacol. Physiol. 41 2014 650 656
31. S. Haffner, M. Temprosa, J. Crandall, S. Fowler, R. Goldberg, E. Horton, S. Marcovina, K. Mather, T. Orchard, R. Ratner, E. Barrett-Connor Diabetes Prevention Program Research Group Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance Diabetes 54 2005 1566 1572
32. D.E. Harrison, R. Strong, Z.D. Sharp, J.F. Nelson, C.M. Astle, K. Flurkey, N.L. Nadon, J.E. Wilkinson, K. Frenkel, C.S. Carter, and et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice Nature 460 2009 392 395
33. D.E. Harrison, R. Strong, D.B. Allison, B.N. Ames, C.M. Astle, H. Atamna, E. Fernandez, K. Flurkey, M.A. Javors, N.L. Nadon, and et al. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males Aging Cell 13 2014 273 282
34. K.S. Jadhav, C.M. Dungan, and D.L. Williamson Metformin limits ceramide-induced senescence in C2C12 myoblasts Mech. Ageing Dev. 134 2013 548 559
35. S.C. Johnson, P.S. Rabinovitch, and M. Kaeberlein mTOR is a key modulator of ageing and age-related disease Nature 493 2013 338 345
36. E. Karnevi, K. Said, R. Andersson, and A.H. Rosendahl Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells BMC Cancer 13 2013 235
37. E. Kickstein, S. Krauss, P. Thornhill, D. Rutschow, R. Zeller, J. Sharkey, R. Williamson, M. Fuchs, A. Köhler, H. Glossmann, and et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling Proc. Natl. Acad. Sci. USA 107 2010 21830 21835
38. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 2002 393 403
39. W.C. Knowler, S.L. Eldelstein, R.B. Goldberg, R.T. Ackermann, J.P. Crandall, J.C. Florez, S.E. Fowler, W.H. Herman, E.S. Horton, S.E. Kahn, et al. Diabetes Prevention Program Research Group HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial Diabetes Care 38 2015 51 58
40. A. Kooy, J. de Jager, P. Lehert, D. Bets, M.G. Wulffelé, A.J. Donker, and C.D. Stehouwer Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus Arch. Intern. Med. 169 2009 616 625
41. S. Kordes, M.N. Pollak, A.H. Zwinderman, R.A. Mathôt, M.J. Weterman, A. Beeker, C.J. Punt, D.J. Richel, and J.W. Wilmink Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial Lancet Oncol. 16 2015 839 847
42. J.D. Lalau, A. Vermersch, L. Hary, M. Andrejak, F. Isnard, and J. Quichaud Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly) Int. J. Clin. Pharmacol. Ther. Toxicol. 28 1990 329 332
43. G.W. Landman, N. Kleefstra, K.J. van Hateren, K.H. Groenier, R.O. Gans, and H.J. Bilo Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 Diabetes Care 33 2010 322 326
44. M.S. Lee, C.C. Hsu, M.L. Wahlqvist, H.N. Tsai, Y.H. Chang, and Y.C. Huang Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals BMC Cancer 11 2011 20
45. C.P. Lexis, I.C. van der Horst, E. Lipsic, W.G. Wieringa, R.A. de Boer, A.F. van den Heuvel, H.W. van der Werf, R.A. Schurer, G. Pundziute, E.S. Tan, et al. GIPS-III Investigators Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial JAMA 311 2014 1526 1535
46. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, and J.M. Evans New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
47. F. Lien, A. Berthier, E. Bouchaert, C. Gheeraert, J. Alexandre, G. Porez, J. Prawitt, H. Dehondt, M. Ploton, S. Colin, and et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk J. Clin. Invest. 124 2014 1037 1051
48. B. Liu, Z. Fan, S.M. Edgerton, X. Yang, S.E. Lind, and A.D. Thor Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions Cell Cycle 10 2011 2959 2966
49. V.D. Longo, A. Antebi, A. Bartke, N. Barzilai, H.M. Brown-Borg, C. Caruso, T.J. Curiel, R. de Cabo, C. Franceschi, D. Gems, and et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 14 2015 497 510
50. J. Lu, J. Shi, M. Li, B. Gui, R. Fu, G. Yao, Z. Duan, Z. Lv, Y. Yang, Z. Chen, and et al. Activation of AMPK by metformin inhibits TGF-β-induced collagen production in mouse renal fibroblasts Life Sci. 127 2015 59 65
51. J.A. Luchsinger, T. Perez, H. Chang, P. Mehta, J. Steffener, G. Pradabhan, M. Ichise, J. Manly, D.P. Devanand, and E. Bagiella Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial J. Alzheimers Dis. 51 2016 501 514
52. T.C. Ma, J.L. Buescher, B. Oatis, J.A. Funk, A.J. Nash, R.L. Carrier, and K.R. Hoyt Metformin therapy in a transgenic mouse model of Huntington's disease Neurosci. Lett. 411 2007 98 103
53. A. Martin-Montalvo, E.M. Mercken, S.J. Mitchell, H.H. Palacios, P.L. Mote, M. Scheibye-Knudsen, A.P. Gomes, T.M. Ward, R.K. Minor, M.J. Blouin, and et al. Metformin improves healthspan and lifespan in mice Nat. Commun. 4 2013 2192
54. R.A. Miller, D.E. Harrison, C.M. Astle, R.A. Floyd, K. Flurkey, K.L. Hensley, M.A. Javors, C. Leeuwenburgh, J.F. Nelson, E. Ongini, and et al. An Aging Interventions Testing Program: study design and interim report Aging Cell 6 2007 565 575
55. R.A. Miller, D.E. Harrison, C.M. Astle, J.A. Baur, A.R. Boyd, R. de Cabo, E. Fernandez, K. Flurkey, M.A. Javors, J.F. Nelson, and et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice J. Gerontol. A Biol. Sci. Med. Sci. 66 2011 191 201
56. O. Moiseeva, X. Deschênes-Simard, E. St-Germain, S. Igelmann, G. Huot, A.E. Cadar, V. Bourdeau, M.N. Pollak, and G. Ferbeyre Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation Aging Cell 12 2013 489 498
57. M. Monami, C. Colombi, D. Balzi, I. Dicembrini, S. Giannini, C. Melani, V. Vitale, D. Romano, A. Barchielli, N. Marchionni, and et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 34 2011 129 131
58. E.M. Moore, A.G. Mander, D. Ames, M.A. Kotowicz, R.P. Carne, H. Brodaty, M. Woodward, K. Boundy, K.A. Ellis, A.I. Bush, et al. AIBL Investigators Increased risk of cognitive impairment in patients with diabetes is associated with metformin Diabetes Care 36 2013 2981 2987
59. N.L. Nadon, R. Strong, R.A. Miller, J. Nelson, M. Javors, Z.D. Sharp, J.M. Peralba, and D.E. Harrison Design of aging intervention studies: the NIA interventions testing program Age (Dordr.) 30 2008 187 199
60. V. Nair, S. Sreevalsan, R. Basha, M. Abdelrahim, A. Abudayyeh, A. Rodrigues Hoffman, and S. Safe Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors J. Biol. Chem. 289 2014 27692 27701
61. T.P. Ng, L. Feng, K.B. Yap, T.S. Lee, C.H. Tan, and B. Winblad Long-term metformin usage and cognitive function among older adults with diabetes J. Alzheimers Dis. 41 2014 61 68
62. B. Onken, and M. Driscoll Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. Elegans Healthspan via AMPK, LKB1, and SKN-1 PLoS ONE 5 2010 e8758
63. B.I. Pérez-Revuelta, M.M. Hettich, A. Ciociaro, C. Rotermund, P.J. Kahle, S. Krauss, and D.A. Di Monte Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation Cell Death Dis. 5 2014 e1209
64. D. Preiss, S.M. Lloyd, I. Ford, J.J. McMurray, R.R. Holman, P. Welsh, M. Fisher, C.J. Packard, and N. Sattar Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial Lancet Diabetes Endocrinol. 2 2014 116 124
65. B.J. Quinn, M. Dallos, H. Kitagawa, A.B. Kunnumakkara, R.M. Memmott, M.C. Hollander, J.J. Gills, and P.A. Dennis Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling Cancer Prev. Res. (Phila.) 6 2013 801 810
66. Y. Saisho Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect Endocr. Metab. Immune Disord. Drug Targets 15 2015 196 205
67. B. Salani, S. Maffioli, M. Hamoudane, A. Parodi, S. Ravera, M. Passalacqua, A. Alama, M. Nhiri, R. Cordera, and D. Maggi Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells FASEB J. 26 2012 788 798
68. C. Slack, A. Foley, and L. Partridge Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila PLoS ONE 7 2012 e47699
69. D.L. Smith Jr., C.F. Elam Jr., J.A. Mattison, M.A. Lane, G.S. Roth, D.K. Ingram, and D.B. Allison Metformin supplementation and life span in Fischer-344 rats J. Gerontol. A. Biol. Sci. Med. Sci. 65 2010 468 474
70. Y.M. Song, Y.H. Lee, J.W. Kim, D.S. Ham, E.S. Kang, B.S. Cha, H.C. Lee, and B.W. Lee Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway Autophagy 11 2015 46 59
71. R.J. Stevens, R. Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, and et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 2593 2603
72. R. Strong, R.A. Miller, C.M. Astle, R.A. Floyd, K. Flurkey, K.L. Hensley, M.A. Javors, C. Leeuwenburgh, J.F. Nelson, E. Ongini, and et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice Aging Cell 7 2008 641 650
73. M.E. Tinetti, G. McAvay, M. Trentalange, A.B. Cohen, and H.G. Allore Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study BMJ 351 2015 h4984
74. L. Tosca, C. Ramé, C. Chabrolle, S. Tesseraud, and J. Dupont Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells Reproduction 139 2010 409 418
75. C.H. Tseng Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan Eur. J. Endocrinol. 167 2012 409 416
76. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
77. H.J. Whittington, A.R. Hall, C.P. McLaughlin, D.J. Hausenloy, D.M. Yellon, and M.M. Mocanu Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon Cardiovasc. Drugs Ther. 27 2013 5 16
78. J.E. Wilkinson, L. Burmeister, S.V. Brooks, C.C. Chan, S. Friedline, D.E. Harrison, J.F. Hejtmancik, N. Nadon, R. Strong, L.K. Wood, and et al. Rapamycin slows aging in mice Aging Cell 11 2012 675 682
79. Z. Xie, K. Lau, B. Eby, P. Lozano, C. He, B. Pennington, H. Li, S. Rathi, Y. Dong, R. Tian, and et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice Diabetes 60 2011 1770 1778
80. Z. Zheng, H. Chen, J. Li, T. Li, B. Zheng, Y. Zheng, H. Jin, Y. He, Q. Gu, and X. Xu Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin Diabetes 61 2012 217 228